Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 1,868 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diagnosis of Melanoma Clear all
Terminated Phase 1 Interventional

TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy

NCT04596033
View directory record Official record
Conditions
Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Renal Cell Carcinoma, Small-cell Lung Cancer, Cutaneous Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma, Merkel Cell Carcinoma
Interventions
GEN-011, IL-2, Fludarabine, Cyclophosphamide
Biological · Drug
Lead sponsor
Genocea Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Gilbert, Arizona • Tampa, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2022 · Synced Oct 21, 2026, 9:03 PM EDT
Terminated Phase 2 Interventional Results available

A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma

NCT02050321
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Acitretin, Vemurafenib
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 26, 2018 · Synced Oct 21, 2026, 9:03 PM EDT
Completed Phase 2 Interventional

A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors

NCT02576431
View directory record Official record
Conditions
Solid Tumors Harboring NTRK Fusion
Interventions
BAY2757556 (Larotrectinib, Vitrakvi)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
18
States / cities
Palo Alto, California • Santa Monica, California • Pembroke Pines, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 21, 2026, 9:03 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma

NCT00104845
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
human gp100 plasmid DNA vaccine, mouse gp100 plasmid DNA vaccine
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2013 · Synced Oct 21, 2026, 9:03 PM EDT
Terminated Phase 1 Interventional

Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors

NCT02313012
View directory record Official record
Conditions
Neoplasm Metastasis
Interventions
CC-90003
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Los Angeles, California • New Haven, Connecticut • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 21, 2026, 9:03 PM EDT
Completed Phase 2 Interventional Results available

Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma

NCT00071981
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
incomplete Freund's adjuvant, melanoma helper peptide vaccine, multi-epitope melanoma peptide vaccine, sargramostim, tetanus peptide melanoma vaccine
Biological
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
65
States / cities
Palo Alto, California • Stanford, California • Lewes, Delaware + 50 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 21, 2026, 9:03 PM EDT
Active, not recruiting No phase listed Observational

A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors

NCT05812027
View directory record Official record
Conditions
Head and Neck Cancer, Cervical Cancer, Non Small Cell Lung Cancer, HPV16 Related Cancers, Sarcoma, Uveal Melanoma, NUT Carcinoma
Interventions
Tumor and HLA Profiling
Diagnostic Test
Lead sponsor
TScan Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
21
States / cities
Scottsdale, Arizona • San Diego, California • New Haven, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Oct 21, 2026, 9:03 PM EDT
Completed Phase 1 Interventional

Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Melanoma or Brain Tumors

NCT00002754
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Melanoma (Skin), Metastatic Cancer
Interventions
monoclonal antibody Me1-14 F(ab')2
Biological
Lead sponsor
Duke University
Other
Eligibility
3 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2001
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Oct 21, 2026, 9:03 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma

NCT01029873
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Cisplatin, ALT-801
Drug · Biological
Lead sponsor
Altor BioScience
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
8
States / cities
Los Angeles, California • Orlando, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 21, 2026, 9:03 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Optical Biopsy of Human Skin in Conjunction With Laser Treatment

NCT00540566
View directory record Official record
Conditions
Malignant Melanoma, Merkel Cell Carcinoma, Basal Cell Carcinoma, Squamous Cell Carcinoma, Atypical Nevi, Congenital Nevi, Seborrheic Keratosis, Paget's Disease, Dermatofibroma, Kaposi's Sarcoma, Port Wine Stain, Hemangioma, Tattoos, Scleroderma, Burns
Interventions
Optical Biopsy imaging
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 75 Years
Enrollment
113 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2008
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Oct 21, 2026, 9:03 PM EDT
Terminated Phase 1 Interventional Results available

Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors

NCT03991741
View directory record Official record
Conditions
Metastatic Melanoma, Locally Advanced Refractory/Recurrent Melanoma, Metastatic Head and Neck Cancer, Locally Advanced Refractory/Recurrent Head and Neck Cancer
Interventions
Autologous Tumor Infiltrating Lymphocytes, High-Dose Interleukin 2
Biological
Lead sponsor
Gregory Daniels
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 21, 2026, 9:03 PM EDT
Completed Phase 1 Interventional Results available

A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma

NCT02434354
View directory record Official record
Conditions
Malignant Melanoma
Interventions
pembrolizumab
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 16, 2022 · Synced Oct 21, 2026, 9:03 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

In Vivo Real-time Detection of Circulating Melanoma Cells

NCT01776905
View directory record Official record
Conditions
Melanoma
Interventions
Not listed
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 80 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2027
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 21, 2026, 9:03 PM EDT
Active, not recruiting Phase 3 Interventional

An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma

NCT05022901
View directory record Official record
Conditions
Metastatic Ocular Melanoma, Metastatic Uveal Melanoma
Interventions
Melphalan (3 mg/kg IBW) with Hepatic Delivery System (HDS)
Combination Product
Lead sponsor
Delcath Systems Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
5
States / cities
Palo Alto, California • Tampa, Florida • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 21, 2026, 9:03 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer

NCT01217411
View directory record Official record
Conditions
Adult Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma, HER2/Neu Negative, HER2/Neu Positive, Male Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma, Recurrent Melanoma, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Cognitive Assessment, Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Stereotactic Radiosurgery, Whole-Brain Radiotherapy
Procedure · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 21, 2026, 9:03 PM EDT
Completed Phase 2 Interventional

Everolimus in Treating Patients With Stage IV Melanoma

NCT00098553
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
everolimus
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
94
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Aurora, Illinois + 60 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Oct 21, 2026, 9:03 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma

NCT01350401
View directory record Official record
Conditions
Melanoma
Interventions
Autologous genetically modified T cells, NY-ESO-1ᶜ²⁵⁹T
Genetic
Lead sponsor
Adaptimmune
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
2
States / cities
New Haven, Connecticut • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Oct 21, 2026, 9:03 PM EDT
Terminated Phase 2 Interventional Results available

Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)

NCT06984328
View directory record Official record
Conditions
Cutaneous Melanoma, Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID), Metastatic Cutaneous Melanoma (Stage IV)
Interventions
Acasunlimab, Pembrolizumab
Biological
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 21, 2026, 9:03 PM EDT
Completed Phase 3 Interventional Results available

A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma

NCT00864253
View directory record Official record
Conditions
Malignant Melanoma
Interventions
ABI-007, Dacarbazine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
38
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Oct 21, 2026, 9:03 PM EDT
Completed Phase 1 Interventional

Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody

NCT00431275
View directory record Official record
Conditions
Melanoma
Interventions
CP-675,206
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
8
States / cities
Scottsdale, Arizona • Aurora, Colorado • Aventura, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Oct 21, 2026, 9:03 PM EDT
Completed Phase 1 Interventional

Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma

NCT00580320
View directory record Official record
Conditions
Melanoma, Soft Tissue Sarcoma, Parathyroid Carcinoma, Small Cell Carcinoma of the Lung, Carcinoid Tumors
Interventions
Dacarbazine and bortezomib
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
2
States / cities
Lebanon, New Hampshire • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 18, 2016 · Synced Oct 21, 2026, 9:03 PM EDT
Recruiting No phase listed Observational

Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types

NCT06075524
View directory record Official record
Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Lung Carcinoma, Locally Advanced Malignant Solid Neoplasm, Locally Advanced Melanoma, Metastatic Lung Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Electronic Health Record Review
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 21, 2026, 9:03 PM EDT
Active, not recruiting Phase 1 Interventional

Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer

NCT02298959
View directory record Official record
Conditions
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Colorectal Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Ovarian Carcinoma, Metastatic Renal Cell Carcinoma, Platinum-Resistant Ovarian Carcinoma, Recurrent Melanoma, Recurrent Renal Cell Carcinoma, Refractory Melanoma, Refractory Renal Cell Carcinoma, Sarcoma, Stage IV Colorectal Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Elastography, Pembrolizumab, Ziv-Aflibercept
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
7
States / cities
Tampa, Florida • Bethesda, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 21, 2026, 9:03 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate Safety and Therapeutic Activity of RO6874281 in Combination with Pembrolizumab, in Participants with Advanced or Metastatic Melanoma

NCT03875079
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
RO6874281, Pembrolizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
New Haven, Connecticut • Iowa City, Iowa • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Oct 21, 2026, 9:03 PM EDT